Deal-Making
Lilly going bigger on obesity with Versanis buy
Deal MakingLilly going bigger on obesity with Versanis buyLilly going bigger on obesity with Versanis buy
Eli Lilly will pay up to $1.925 billion to acquire biotech Versanis, adding its Phase II obesity candidate bimagrumab to its pipeline.